PKMYT1 inhibitor(Satya Pharma)(PKMYT1 inhibitor(Satya Pharma)) - 药物靶点：PKMYT1_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

化学药

别名-

靶点

PKMYT1

作用机制

PKMYT1抑制剂(protein kinase, membrane associated tyrosine/threonine 1 inhibitors)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Satya Pharma Innovations Pvt Ltd.

在研机构

Satya Pharma Innovations Pvt Ltd.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 PKMYT1 inhibitor(Satya Pharma) 相关的临床结果

登录后查看更多信息

100 项与 PKMYT1 inhibitor(Satya Pharma) 相关的转化医学

登录后查看更多信息

100 项与 PKMYT1 inhibitor(Satya Pharma) 相关的专利（医药）

登录后查看更多信息

1

项与 PKMYT1 inhibitor(Satya Pharma) 相关的文献（医药）

2024-10-24·Journal of Medicinal Chemistry

Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial

Review

作者: Yang, Ming ; Luo, Guoshun ; Xiang, Hua

\Protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1), an overlooked member of the WEE family responsible for regulating cell cycle transition, has recently emerged as a compelling therapeutic target for precision cancer therapy due to its established synthetic lethal relationship with CCNE1 (cyclin E1) amplification. Since the first-in-class selective PKMYT1 inhibitor, RP-6306, entered clinical trials in 2021, the field has experienced renewed interest underscored by the growing number of inhibitor patents and the exploration of additional gene alterations, such as KRAS/p53 mutations, FBXW7 mutation, and PPP2R1A mutation, as novel synthetic lethal partners. This perspective summarizes, for the first time, the PKMYT1 structure, function, and inhibitors in both the literature and patent applications reported to date. Compounds are described focusing on their design and optimization process, structural features, and biological activity with the aim to promoting further drug discovery efforts targeting PKMYT1 as a potential precision therapy.

100 项与 PKMYT1 inhibitor(Satya Pharma) 相关的药物交易

登录后查看更多信息